1. Merging lithium carbenoid homologation and enzymatic reduction: A combinative approach to the HIV-protease inhibitor Nelfinavir
- Author
-
Andrés R. Alcántara, Laura De Luca, Wolfgang Holzer, Laura Ielo, Laura Castoldi, Pilar Hoyos, Vittorio Pace, and María J. Hernáiz
- Subjects
Drug Synthesis ,Homologation ,Alcohol ,010402 general chemistry ,01 natural sciences ,Biochemistry ,Homologation, Lithium carbenoids, Enzymatic reductions, Drug Synthesis, a-haloketones, Halohydrins, Selectivity, Halohydrins, Biochemistry, Drug Discovery3003, Pharmaceutical Science, Organic Chemistry ,a-haloketones ,chemistry.chemical_compound ,Amide ,Drug Discovery ,medicine ,HIV Protease Inhibitor ,Selectivity ,Selective reduction ,Carbenoid ,chemistry.chemical_classification ,010405 organic chemistry ,Organic Chemistry ,Lithium carbenoids ,Diastereomer ,Combinatorial chemistry ,0104 chemical sciences ,Enzymatic reductions ,Halohydrins ,Nelfinavir ,Enzyme ,chemistry ,medicine.drug - Abstract
An effective stereocontrolled synthesis of the HIV protease inhibitor Nelfinavir is reported. Two transformations were identified crucial for achieving success: the formation of a densely functionalized α-chloroketone via the homologation of a Weinreb amide with chloromethyllithium (LiCH2Cl), followed by its erythro selective reduction into the corresponding chiral chlorohydrin. A commercially available enzyme P2-C02 was particularly well suited for this purpose, affording the key alcohol (in an excellent 99% de), which was then smoothly converted into the active biologically active agent.
- Published
- 2018